Page 5 - Solid Biosciences Inc News Today

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) and Telix Pharmaceuticals (OTCMKTS:TLPPF – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Valuation & Earnings This table compares Ultragenyx Pharmaceutical […]

- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, ...

STATEMENT OF EXECUTIVE COMPENSATION This Statement of Executive Compensation is filed by ImmunoPrecise Antibodies Ltd. pursuant to Section 11.6 of National...

Great Point Partners LLC acquired a new stake in shares of Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 210,405 shares of the company’s stock, valued at approximately $997,000. Great Point Partners LLC owned […]

/PRNewswire/ -- The Duchenne muscular dystrophy (DMD) therapeutics market size is expected to grow by USD 2.39 billion from 2022 to 2027. In addition, the...

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Stock analysts at Leerink Partnrs boosted their Q3 2023 earnings per share (EPS) estimates for shares of Solid Biosciences in a report released on Wednesday, August 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($1.05) for the quarter, […]

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Equities research analysts at Leerink Partnrs raised their Q3 2023 earnings per share (EPS) estimates for Solid Biosciences in a research note issued to investors on Wednesday, August 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($1.05) per share for […]

NantHealth Inc is expected to report for 2Q. Nicholas Financial is expected to report for 1Q. Orbital Infrastructure Group Inc is expected to report for 2Q. Outlook Therapeutics Inc ... -Today at 06:23 am- MarketScreener

– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy – – Executed licensing agreement for development and... -Today at 04:18 pm- MarketScreener

Anika (ANIK) delivered earnings and revenue surprises of 44.12% and 9.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?